NEW YORK (AP) -- Shares of United Therapeutics Corp. rose Thursday after data showed that an inhaled version of its drug candidate to treat pulmonary arterial hypertension met its goal in a late-stage trial. The drug, Viveta, is an inhaled version of United Therapeutics’ Remodulin, which is given either as an injection under the skin or intravenously. Pulmonary arterial hypertension, or PAH, is a condition of elevated blood pressure in the lungs’ blood vessels. A complete analysis of the data, released Wednesday at the American Thoracic Society conference, demonstrated that patients taking Viveta walked further in six minutes than those taking a placebo.
